(AHCO) Adapthealth - Ratings and Ratios

AdaptHealth Corp is a leading distributor of home medical equipment and related services in the United States, catering to patients with various chronic conditions, including obstructive sleep apnea, diabetes, and wound care needs. The companys comprehensive product portfolio includes sleep therapy equipment, continuous glucose monitors, insulin pumps, oxygen concentrators, wheelchairs, and other essential medical supplies.

By providing a wide range of medical devices and supplies, AdaptHealth Corp plays a vital role in supporting patients healthcare needs, particularly those discharged from acute care facilities. The companys services are utilized by beneficiaries of Medicare, Medicaid, and commercial insurance payors, underscoring its significance in the healthcare ecosystem.

From a technical analysis perspective, AHCOs stock price is currently at $8.62, below its 20-day and 50-day simple moving averages (SMA20: $8.91, SMA50: $8.70). However, the stock is showing signs of potential recovery, as it is above its 52-week low of $7.33. The Average True Range (ATR) of 0.36 indicates a relatively stable price movement, with a daily volatility of 4.18%. Given the current technical setup, a potential price target could be the 200-day simple moving average (SMA200) of $9.86, representing a 14.4% upside from the current price.

Fundamentally, AdaptHealth Corp has a market capitalization of $1.21 billion and a price-to-earnings (P/E) ratio of 15.48, indicating a relatively reasonable valuation. The forward P/E ratio of 9.07 suggests expected earnings growth, potentially driven by the increasing demand for home medical equipment and related services. With a return on equity (RoE) of 5.56%, the company demonstrates a decent ability to generate profits for its shareholders. Considering the fundamental data and the technical analysis, a forecast for AHCOs stock price could be a potential increase to $10.50 in the next 6-12 months, representing a 21.7% upside from the current price, driven by the companys solid fundamentals and potential technical recovery.